Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Assets: 2019-2024

Historic Non-Current Assets for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $91.8 million.

  • C4 Therapeutics' Non-Current Assets fell 42.99% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 42.99%. This contributed to the annual value of $91.8 million for FY2024, which is 12.76% down from last year.
  • As of FY2024, C4 Therapeutics' Non-Current Assets stood at $91.8 million, which was down 12.76% from $105.3 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Non-Current Assets registered a high of $181.1 million during FY2021, and its lowest value of $19.1 million during FY2020.
  • For the 3-year period, C4 Therapeutics' Non-Current Assets averaged around $113.5 million, with its median value being $105.3 million (2023).
  • In the last 5 years, C4 Therapeutics' Non-Current Assets soared by 846.60% in 2021 and then dropped by 26.54% in 2023.
  • Yearly analysis of 5 years shows C4 Therapeutics' Non-Current Assets stood at $19.1 million in 2020, then surged by 846.60% to $181.1 million in 2021, then dropped by 20.87% to $143.3 million in 2022, then decreased by 26.54% to $105.3 million in 2023, then declined by 12.76% to $91.8 million in 2024.